Cargando…
AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
OBJECTIVE: Multiple myeloma (MM) is the clonal proliferation of neoplastic plasma cells in the bone marrow. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, drug resistance is a major problem. OncomiR-19a plays an oncogenic role in many cancers, including MM; however, the functio...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Royan Institute
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588822/ https://www.ncbi.nlm.nih.gov/pubmed/34837676 http://dx.doi.org/10.22074/cellj.2021.7302 |